About Kronos Bio
Kronos Bio is a company based in San Mateo (United States) founded in 2017 was acquired by Concentra Biosciences in May 2025.. Kronos Bio has raised $271.01 million across 3 funding rounds from investors including Fidelity Investments, BlackRock and Citadel. The company has 97 employees as of December 31, 2022. Kronos Bio operates in a competitive market with competitors including Sana Biotechnology, Janux Therapeutics, GigaGen, Carisma Therapeutics and Asher Biotherapeutics, among others.
- Headquarter San Mateo, United States
- Employees 97 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Kronos Bio, Inc.
-
Annual Revenue
$9.85 M57as on Dec 31, 2024
-
Net Profit
$-86.08 M24as on Dec 31, 2024
-
EBITDA
$-92.89 M24as on Dec 31, 2024
-
Total Equity Funding
$271.01 M (USD)
in 3 rounds
-
Latest Funding Round
$148 M (USD), Series B
Aug 24, 2020
-
Investors
Fidelity Investments
& 19 more
-
Employee Count
97
as on Dec 31, 2022
-
Acquired by
Concentra Biosciences
(May 01, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Kronos Bio
Kronos Bio has successfully raised a total of $271.01M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $148 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $148.0M
-
First Round
First Round
(23 May 2018)
- Investors Count 19
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2020 | Amount | Series B - Kronos Bio | Valuation | Perceptive Advisors | |
| Jul, 2019 | Amount | Series A - Kronos Bio | Valuation | Vida Ventures , Omega Funds | |
| May, 2018 | Amount | Seed - Kronos Bio | Valuation | Omega Funds , Bellco Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Kronos Bio
Kronos Bio has secured backing from 20 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Fidelity Investments, BlackRock and Citadel. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Venture capital is provided to healthcare startups by Commodore Capital.
|
Founded Year | Domain | Location | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Kronos Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Kronos Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kronos Bio Comparisons
Competitors of Kronos Bio
Kronos Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Janux Therapeutics, GigaGen, Carisma Therapeutics and Asher Biotherapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer treatment are developed to target solid tumors.
|
|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| domain | founded_year | HQ Location |
Chimeric antigen receptor macrophages are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of cancer and autoimmune diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Kronos Bio
Frequently Asked Questions about Kronos Bio
When was Kronos Bio founded?
Kronos Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is Kronos Bio located?
Kronos Bio is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Is Kronos Bio a funded company?
Kronos Bio is a funded company, having raised a total of $271.01M across 3 funding rounds to date. The company's 1st funding round was a Seed of $18.01M, raised on May 23, 2018.
How many employees does Kronos Bio have?
As of Dec 31, 2022, the latest employee count at Kronos Bio is 97.
What is the annual revenue of Kronos Bio?
Annual revenue of Kronos Bio is $9.85M as on Dec 31, 2024.
What does Kronos Bio do?
Kronos Bio was founded in 2017 and is based in San Mateo, United States. Operations focus on the biotechnology sector, where small molecule-based therapeutics are created to address cancer. These molecules are designed to bind directly to target proteins, interfere with their activity, disrupt protein-protein complexes, or influence adjacent proteins for indirect modulation. The companys domain is kronosbio.com.
Who are the top competitors of Kronos Bio?
Kronos Bio's top competitors include Janux Therapeutics, Sana Biotechnology and GigaGen.
Who are Kronos Bio's investors?
Kronos Bio has 20 investors. Key investors include Fidelity Investments, BlackRock, Citadel, Perceptive Advisors, and Commodore Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.